Reimbursed with a limitationGenericATC V03AC03

Deferasirox Spirig HC

Deferasirox Spirig HC is a generic from Spirig HealthCare AG and is listed on the FOPH Specialities List. Basic health insurance reimburses it within the authorised indication. The public price ranges from CHF 172.40 to CHF 2'209.20 depending on the pack; the co-payment is 10 per cent.

Core data

Authorisation holder
Spirig HealthCare AG
ATC code
V03AC03
IT group
06.99 Varia
Active substances
Deferasiroxum
Preparation type
Generic
On the SL since
01/09/2024
Last price change
01/04/2025
Co-payment
10%

Prices per pack

The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.

Deferasirox Spirig HC Price table As of 17/09/2026
Dosage formPack sizeEx-factory pricePublic priceValid fromCat.GTIN
Filmtabl 90 mgBlist 30 StkCHF 143.41CHF 172.4001/09/2024B7680688710014
Filmtabl 90 mgBlist 90 StkCHF 365.68CHF 414.1001/09/2024B7680688710021
Filmtabl 180 mgBlist 30 StkCHF 235.19CHF 272.2001/09/2024B7680688710038
Filmtabl 180 mgBlist 90 StkCHF 599.72CHF 668.6501/09/2024B7680688710045
Filmtabl 360 mgBlist 30 StkCHF 385.70CHF 435.9001/09/2024B7680688710052
Filmtabl 360 mgBlist 90 StkCHF 983.53CHF 1'086.0501/09/2024B7680688710069
Filmtabl 900 mgBlist 30 StkCHF 790.68CHF 876.3501/04/2025B7680688710076
Filmtabl 900 mgBlist 90 StkCHF 2'016.23CHF 2'209.2001/04/2025B7680688710083

Limitation

This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.

The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.

FOPH wordingValid from 01/09/2024

Eine Vergütung erfolgt
 - als Erstlinientherapie zur Behandlung der chronischen Eisenüberladung auf Grund häufiger Transfusionen bei Patienten mit Beta-Thalassämia major.
 - für die Behandlung von weiteren chronischen, transfusionsbedingten Eisenüberladungen, wenn eine Deferoxamin-Therapie kontraindiziert oder unangemessen ist.
 - für die Behandlung der chronischen Eisenüberladung bei Patienten mit nicht transfusionsabhängigen Thalassämie-Syndromen im Alter von 10 Jahren und älter, wenn eine Deferoxamin-Therapie kontraindiziert oder unangemessen ist.

Therapien, die vor der Einführung der angepassten Limitierung (1. Juni 2023) begonnen wurden, werden weiterhin vergütet, sofern es sich um eine Behandlung entsprechend der von Swissmedic zugelassenen Indikation handelt.

More preparations in this group

FAQ

Is Deferasirox Spirig HC covered by Swiss health insurance?

Yes, but only under conditions. Deferasirox Spirig HC is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.

What does Deferasirox Spirig HC cost in Switzerland?

The public price is the maximum price set by the FOPH and for Deferasirox Spirig HC ranges from CHF 172.40 to CHF 2'209.20 per pack. The ex-factory price ranges from CHF 143.41 to CHF 2'016.23. Pharmacies may not charge more, but may charge less.

Correct or complete this entry

Market access

Do you need your product on the Specialities List?

Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.

  • Independent directory
  • Official FOPH data
  • Website in eight languages
Send an enquiry
Contact

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissreimbursement.com